United Therapeutics CEO Martine Rothblatt Sells $5.65M in Stock via 10b5-1 Plan

United Therapeutics Corp ($UTHR) Form 4 Filing Analysis

Executive Overview

On October 30, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, reported the exercise of options for 9,500 shares of common stock at an exercise price of $117.76 per share and the subsequent sale of all 9,500 shares on October 29, 2026. The gross proceeds generated from the sale totaled approximately $5.65 million, executed at weighted-average prices ranging from $590.43 to $599.30 per share.

Transaction Details

• Option Exercise: Exercised 9,500 stock options expiring on March 15, 2027, with an exercise price of $117.76 per share.
• Open Market Sales: Sold across nine tranches totaling 9,500 shares with an aggregate transaction value of $5,650,414.51 (average price of ~$594.78 per share).
• Ownership Nature: Held indirectly through a family trust.

Plan and Context

• Rule 10b5-1 Plan: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan covers the exercise and liquidation of up to 1,734,410 stock options scheduled to expire on March 15, 2027, running through December 31, 2026, unless completed earlier.
• Post-Transaction Holdings: Following these transactions, the reporting person continues to hold significant beneficial ownership in United Therapeutics, including 324,443 shares in this specific family trust, 40,513 shares held directly, and over 303,000 additional shares distributed across various family trusts and spousal holdings, alongside 128,910 remaining stock options in the trust.

Significance Assessment

The trading significance is evaluated as Low. Although the nominal value is meaningful ($5.65 million), the activity reflects an automatic, scheduled exercise and sale under an established Rule 10b5-1 trading plan addressing options nearing their March 2027 expiration. The CEO retains a substantial long-term equity stake in the company.